Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This retrospective pharmacovigilance study reviewed adverse event reports from 2004 to 2025 for drugs treating benign prostatic hyperplasia, identifying distinct safety signals for α1-blockers, 5ARIs, and PDE5I, including some potential new adverse events that require further investigation.

This study found that in men with benign prostatic hyperplasia, 5-alpha reductase inhibitors significantly increased the risk of gynecomastia and breast tenderness compared to placebo or alpha-blockers.

This study found that 5-α reductase inhibitors do not significantly increase the risk of erectile dysfunction in men with benign prostatic hyperplasia or alopecia, although duration of benign prostatic hyperplasia may elevate risk.

This study found that combining 5-alpha reductase inhibitors with alpha-blockers provided the best symptomatic relief and reduced the risk of clinical progression for BPH, while PDE5 inhibitors could offset sexual side effects.

This review discusses recent developments in α1-adrenoceptor antagonists and 5α-reductase inhibitors for treating benign prostatic hyperplasia, reporting no new clinical results while identifying potential areas for future drug development.

This review examines hormonal influences on acne development and available hormonal therapies but reports no new clinical results.

This article reviews the effects of various medications on male fertility, noting that while commonly used drugs can mostly have reversible impacts, conclusive human evidence remains limited.

Male androgenetic alopecia involves hair follicle miniaturization due to DHT, with potential treatments using inhibitors and blockers.

Dutasteride and finasteride don't raise erectile dysfunction risk.

This study found that pubic skin fibroblasts respond to androgens, increasing 5α-reductase activity via an androgen receptor-mediated mechanism, suggesting its potential as a marker of androgen action in vitro.

In this study, clozapine reduced suicide-related behaviors in a schizophrenia-like mouse model, but its effects on exploratory behavior were counteracted by the neurosteroid inhibitor finasteride.

This study discusses how chronic ethanol exposure and withdrawal affect GABAA receptor subunit expression and function, finding that some changes can be selectively blocked by certain drugs like diazepam and finasteride.

Finasteride blocks progesterone's effect on absence seizures in rats.

This review discusses the management of androgenic disorders in women, highlighting that treatment is generally more effective than recognized, though improvement may take weeks or months to appear.

Hormones, especially androgens, play a key role in causing acne, and treatments like hormone control pills and hormone-blocking medications can help.

In this study, ethanol was found to enhance GABAergic neurosteroid production and inhibit long-term potentiation in rat hippocampal slices via unblocked NMDA receptor activation, effects reversible by specific inhibitors.

In this study, male-derived brain tissue exhibited higher cell death following ischemia compared to female-derived tissue, and certain steroid hormones showed different neuroprotective effects depending on the sex of the tissue.

Dutasteride reduces DHT more effectively than finasteride.

This abstract discusses the unclear role of dihydrotestosterone (DHT) in postembryonic life in marsupials and possibly humans, reporting no new findings.

This review discusses the role of inheritance, androgens, and microinflammation in androgenetic alopecia and suggests some plant-based folk remedies may help address these factors but reports no new clinical results.

This review discusses the role of 5α-reductase enzymes in androgen action and related disorders, noting that their specific inhibitory drugs show promise for conditions like benign prostatic hypertrophy; it reports no new clinical results.

In this study, there was no evidence that using 5α-reductase inhibitors for either short or long durations increased the risk of male breast cancer.

This study found that overexpression of AKR1C3 in prostate cancer cells redirected androgen metabolism towards testosterone production, which facilitated cell proliferation, potentially reducing the effectiveness of finasteride treatment.

This study suggests that 5-alpha reductase inhibitors may reduce invasive cancer features and improve survival in men undergoing radical cystectomy for high-grade urothelial carcinoma, although further research is needed to confirm these findings.

This study suggests that the use of 5α-reductase inhibitors in men may be associated with macular abnormalities, characterized by cystoid changes and foveal cavitation, potentially progressing to more severe defects.

This study found no positive association between the use of 5α-reductase inhibitors and the risk of male breast cancer.

This meta-analysis concluded that 5α-reductase inhibitors may increase the risk of mild depression, particularly with dutasteride, in patients treated for benign prostatic hyperplasia and androgenic alopecia.

This study examined the dementia risk in patients with benign prostatic hyperplasia using alpha-blockers and 5-alpha reductase inhibitors, finding no significant association between these medications and increased dementia risk compared to no treatment, but noted higher risk probabilities for certain 5ARIs.

This study suggests that finasteride may inhibit the enzyme PNMT, potentially contributing to its sexual and psychological side effects.

Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.